Oncology-focused biopharmaceutical company Citius Oncology Inc (Nasdaq:CTOR), a majority-owned subsidiary of Citius Pharmaceuticals Inc (Nasdaq:CTXR), announced on Monday preliminary, unaudited LYMPHIR (denileukin diftitox-cxdl) unit sales to US wholesalers and institutional vial orders for its fiscal fourth quarter ended 30 September 2026.

A total of 792 units were purchased by US wholesalers in the three-month period, compared to 360 units in the three months to 30 June 2026, an increase of 120%.

Additionally, 950 LYMPHIR vials were ordered by prescribing centres from wholesalers, compared to 926 in the prior quarter.

To date, 54 institutions have ordered LYMPHIR, compared to 44 as of 14 August 2026, as last reported.

LYMPHIR is a targeted immunotherapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) indicated for use in Stage I-III disease after at least one prior systemic therapy. LYMPHIR was approved by the FDA and subsequently launched in the United States in December 2025.